COVID-19 Asymptomatic Testing with POC LumiraDx SARS-CoV-2 Antigen Test
Performance of the LumiraDx Microfluidic Immunofluorescence Point-of-Care SARS-CoV-2 Antigen Test in Asymptomatic Adults and Children
American Journal of Clinical Pathology
Accurate diagnosis is essential for identifying and managing coronavirus disease 2019 (COVID-19) in point-of-care settings and for the implementation of effective infection-control measures.
Currently, the most sensitive testing method for the presence of SARS-CoV-2 is reverse transcription–polymerase chain reaction (RT-PCR) using nasopharyngeal swabs, which poses challenges to community-based asymptomatic screening, such as the requirement for laboratory testing and subsequent delays in reporting results to individuals, who may not isolate themselves until their result has been confirmed.
COVID-19 Asymptomatic Testing
In view of these challenges, this research study investigated the LumiraDx SARS-CoV-2 Ag Test as an aid in COVID-19 asymptomatic testing of infection in adults and children in 5 point-of-care (POC) settings. The results show high agreement between the LumiraDx SARS-CoV-2 Ag Test and the reference RT-PCR test in asymptomatic participants who had been in recent contact with a COVID-19–positive individual or undergoing testing for work purposes
The LumiraDx SARS-CoV-2 Ag Test evaluation in asymptomatic patients demonstrated 82.1% positive percent agreement and 100% negative percent agreement compared with reverse transcription–polymerase chain reaction.
This study suggests that the microfluidic immunofluorescence point-of-care LumiraDx SARS-CoV-2 Ag Test is a valuable tool for the rapid screening of individuals without symptoms in both community and health care settings to limit the spread of COVID-19.